229 related articles for article (PubMed ID: 17922043)
1. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.
Pham RN; Gooley TA; Keeney GE; Press OW; Pagel JM; Greisman HA; Bensinger WI; Holmberg LA; Petersdorf SH; Maloney DG; Gopal AK
Bone Marrow Transplant; 2007 Dec; 40(11):1039-44. PubMed ID: 17922043
[TBL] [Abstract][Full Text] [Related]
2. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
[TBL] [Abstract][Full Text] [Related]
3. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
4. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
5. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
[TBL] [Abstract][Full Text] [Related]
6. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL
Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
Vose JM; Bierman PJ; Loberiza FR; Lynch JC; Bociek GR; Weisenburger DD; Armitage JO
Biol Blood Marrow Transplant; 2008 Jan; 14(1):36-42. PubMed ID: 18158959
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience.
López R; Martino R; Sureda A; Nomdedéu J; Briones J; Martin-Henao G; García J; Brunet S; Sierra J
Haematologica; 1999 Apr; 84(4):350-5. PubMed ID: 10190950
[TBL] [Abstract][Full Text] [Related]
9. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
Kang TY; Rybicki LA; Bolwell BJ; Thakkar SG; Brown S; Dean R; Sekeres MA; Advani A; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2007 Nov; 40(10):973-8. PubMed ID: 17873917
[TBL] [Abstract][Full Text] [Related]
10. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
11. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.
Hamadani M; Benson DM; Lin TS; Porcu P; Blum KA; Devine SM
Eur J Haematol; 2008 Dec; 81(6):425-31. PubMed ID: 18774954
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
14. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Avivi I; Montoto S; Canals C; Maertens J; Al-Ali H; Mufti GJ; Finke J; Schattenberg A; Fanin R; Cornelissen JJ; Vernant JP; Russell N; Beguin Y; Thomson K; Verdonck LF; Kobbe G; Tilly H; Socié G; Sureda A;
Br J Haematol; 2009 Dec; 147(5):719-28. PubMed ID: 19793383
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
[TBL] [Abstract][Full Text] [Related]
16. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
18. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
19. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study.
Feyler S; Prince HM; Pearce R; Towlson K; Nivison-Smith I; Schey S; Gibson J; Patton N; Bradstock K; Marks DI; Cook G
Bone Marrow Transplant; 2007 Sep; 40(5):443-50. PubMed ID: 17589529
[TBL] [Abstract][Full Text] [Related]
20. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
